Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7743)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 14, 2017 (publication date) through Apr 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Deiana S, Gabbani T, Annese V. Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World J Gastroenterol 2017; 23(2): 197-203 [PMID: 28127193 DOI: 10.3748/wjg.v23.i2.197] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i2/197.htm |
| Number | Citing Articles |
| 1 |
Rovshan M. Ismailov, Lieven Pouillon, Christian P. Selinger, Zaytuna D. Khasanova. Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. Expert Opinion on Biological Therapy 2021; 21(1): 111 doi: 10.1080/14712598.2020.1842355
|
| 2 |
Jukyung Kang, Karthik Pisupati, Alexander Benet, Brandon T. Ruotolo, Steven P. Schwendeman, Anna Schwendeman. Infliximab Biosimilars in the Age of Personalized Medicine. Trends in Biotechnology 2018; 36(10): 987 doi: 10.1016/j.tibtech.2018.05.002
|
| 3 |
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologics. Gastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
|
| 4 |
Klaudia Farkas, Tamás Molnár. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Immunotherapy 2018; 10(2): 107 doi: 10.2217/imt-2017-0107
|
| 5 |
Maryam Heidari, Sedigheh Pouya, Kaveh Baghaei, Hamid Asadzadeh Aghdaei, Saeed Namaki, Mohammad Reza Zali, Seyed Mahmoud Hashemi. The immunomodulatory effects of adipose‐derived mesenchymal stem cells and mesenchymal stem cells‐conditioned medium in chronic colitis. Journal of Cellular Physiology 2018; 233(11): 8754 doi: 10.1002/jcp.26765
|
| 6 |
Saurabh Talathi, Kondal R. Kyanam Kabir Baig. Biosimilars in inflammatory bowel disease. Journal of Digestive Diseases 2020; 21(11): 610 doi: 10.1111/1751-2980.12940
|
| 7 |
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L. Lakatos. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry 2019; 26(2): 259 doi: 10.2174/0929867324666170406112304
|
| 8 |
Maria Chiara Ditto, Simone Parisi, Marta Priora, Silvia Sanna, Clara Lisa Peroni, Angela Laganà, Antonio D’Avolio, Enrico Fusaro. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-73183-0
|
| 9 |
Murtaza M. Tambuwala, Mohammed N. Khan, Paul Thompson, Paul A. McCarron. Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis. Drug Delivery and Translational Research 2019; 9(1): 14 doi: 10.1007/s13346-018-00597-9
|
| 10 |
José Diego Marques Santos, Juan Nicolás Peña-Sánchez, Sharyle A. Fowler. Patients’ perspectives on medication for inflammatory bowel disease: a mixed-method systematic review. European Journal of Gastroenterology & Hepatology 2021; 33(9): 1139 doi: 10.1097/MEG.0000000000001861
|